Telomerase therapeutics for cancer: challenges and new directions (original) (raw)

• Moyzis, R. K. et al. A highly conserved repetitive DNA sequence (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl Acad. Sci. USA 85, 6622–6626 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Blackburn, E. H. Telomere states and cell fates. Nature 408, 53–56 (2000).
  Article CAS PubMed Google Scholar
• de Lange, T. Protection of mammalian telomeres. Oncogene 21, 532–540 (2002).
  Article CAS PubMed Google Scholar
• Griffith, J. D. et al. Mammalian telomeres end in a large duplex loop. Cell 97, 503–514 (1999). Provides the first direct evidence that telomeres form a duplex loop instead of ending in a linear fashion.
  Article CAS PubMed Google Scholar
• Blackburn, E. H. Switching and signaling at the telomere. Cell 106, 661–673 (2001).
  Article CAS PubMed Google Scholar
• Wright, W. E., Pereira-Smith, O. M. & Shay, J. W. Reversible cellular senescence: a two-stage model for the immortalization of normal human diploid fibroblasts. Mol. Cell. Biol. 9, 3088–3092 (1989). The first report defining two stages of cellular senescence in human cells.
  CAS PubMed PubMed Central Google Scholar
• Feng, J. et al. The RNA component of human telomerase. Science 269, 1236–1241 (1995). Reports the initial cloning of hTR, the functional or template RNA subunit of human telomerase.
  Article CAS PubMed Google Scholar
• Nakamura, T. M. et al. Telomerase catalytic subunit homologs from fission yeast and humans. Science 277, 955–959 (1997). Reports the initial cloning of hTERT, the catalytic subunit of human telomerase.
  Article CAS PubMed Google Scholar
• Lingner, J. & Cech, T. R. Telomerase and chromosome end maintenance. Curr. Opin. Genet. Dev. 8, 226–232 (1998).
  Article CAS PubMed Google Scholar
• Collins, K. & Mitchell, J. R. Telomerase in the human organism. Oncogene 21, 564–579 (2002).
  Article CAS PubMed Google Scholar
• Nugent, C. I. & Lundblad, V. The telomerase reverse transcriptase: components and regulation. Genes. Dev. 12, 1073–1085 (1998).
  Article CAS PubMed Google Scholar
• Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 173–117 (1996). The first report to demonstrate telomerase activity in human germline and embryonic tissues, and its repression during development.
  Article CAS PubMed Google Scholar
• Aisner, D. L., Wright, W. E. & Shay, J. W. Telomerase regulation: not just flipping the switch. Curr. Opin. Genet. Dev. 12, 80–85 (2002).
  Article CAS PubMed Google Scholar
• Forsyth, N. R, Wright. W. E. & Shay, J. W. Telomerase and differentiation in multicellular organisms:Turn it off, turn it on, and turn it off again. Differentiation 69, 188–197 (2002).
  Article CAS PubMed Google Scholar
• Bodnar, A. G. et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349–352 (1998). First report that the introduction of hTERT is sufficient to produce telomerase activity, maintain or elongate telomeres, and immortalize normal diploid human cells.
  Article CAS PubMed Google Scholar
• Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy Oncogene 23, 2919–2933 (2004).
  Article CAS PubMed Google Scholar
• Shay, J. W. & Wright, W. E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 25, 1–8 (2004).
  Google Scholar
• Shay, J. W. & Wright, W. E. Hayflick, his limit, and cellular ageing. Nature Rev. Mol. Cell Biol. 1, 72–76 (2000).
  Article CAS Google Scholar
• Shay, J. W. & Wright, W. E. Telomeres in dyskeratosis congenita. Nature Genet. 36, 437–438 (2004).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405–413 (1985). First paper to identify the existence of telomerase activity approximately 10 years before the main components, TERT and TR, were cloned.
  Article CAS PubMed Google Scholar
• Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2015 (1994). First report to describe TRAP (PCR-based telomerase activity assay) and to demonstrate telomerase activity in a large panel of primary human cancers but not in normal human tissues.
  Article CAS PubMed Google Scholar
• Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 5, 787–791 (1997). Provides an overview of the diagnostic potential of measuring telomerase activity in human cancer.
  Article Google Scholar
• Shay, J. W. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. Cancer J. Sci. Am. (Suppl. 1), S26–S34 (1998).
• Hodes, R. Molecular targeting of cancer: telomeres as targets. Proc. Natl Acad. Sci. USA 98, 7649–7651 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Saretzki, G. Telomerase inhibition as cancer therapy. Cancer Letter. 194, 209–219 (2003).
  Article CAS Google Scholar
• Kelland, L. R. Telomerase: biology and phase I trials. Lancet Oncol. 2, 95–102 (2001).
  Article CAS PubMed Google Scholar
• White, L. K., Wright, W. E. & Shay, J. W. Telomerase inhibitors. Trends Biotechnol. 19, 114–120 (2001).
  Article CAS PubMed Google Scholar
• Shay, J. W. & Wright, W. E. Mechanism-based combination telomerase inhibition therapy. Cancer Cell. 7, 1–2 (2005).
  Article CAS PubMed Google Scholar
• Neidle, S. & Parkinson, G. Telomere maintenance as a target for anticancer drug discovery. Nature Rev. Drug Discov. 1, 383–393 (2002).
  Article CAS Google Scholar
• Helder, M. N., Wisman, G. B. A. & van der Zee, A. G. J. Telomerase and telomeres: from basic biology to cancer treatment. Cancer Invest. 20, 82–101 (2002).
  Article CAS PubMed Google Scholar
• Blasco, M. A. Telomeres and human disease: ageing, cancer and beyond. Nature Rev. Genet. 6, 611–622 (2005).
  Article CAS PubMed Google Scholar
• McKenzie, K. E., Umbricht C. B. & Sukumar S. Applications of telomerase research in the fight against cancer. Mol. Med. Today 5, 114–122 (1999).
  Article CAS PubMed Google Scholar
• Shay, J. W. Meeting Report: The role of telomeres and telomerase in cancer. Cancer Res. 65, 3513–3517 (2005).
  Article CAS PubMed Google Scholar
• Gellert, G. C., Jackson, S. R. Dikmen, G., Wright, W. E. & Shay, J. W. Telomerase as a therapeutic target in cancer. Drug Discov. Today 2, 159–164 (2005).
  Article CAS Google Scholar
• Shay, J. W. & Wright W. E. in Telomeres 2nd Edn (Eds. deLange, T., Lundblad, V. Blackburn, E.) 81–108 (Cold Spring Harbor Laboratory, New York, 2005).
  Google Scholar
• Granger M. P., Wright W. E. & Shay J. W. Telomerase in cancer and aging. Crit. Rev. Oncol. Hematol. 4, 29–40 (2002).
  Article Google Scholar
• Shay, J. W. & Gazdar, A. F. Telomerase in the early detection of cancer. J. Clin. Pathol. 50, 106–109 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Gilley, D., Tanaka, H. & Herbert, B.-S. Telomere dysfunction in aging and cancer. Intl J. Biochem. Cell Biol. 37, 1000–1013 (2005).
  Article CAS Google Scholar
• Gowan, S. M. et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 61, 1154–1162 (2002).
  Article CAS PubMed Google Scholar
• Read, M. A. et al. Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships. J. Med. Chem. 42, 4538–4546 (1999).
  Article CAS PubMed Google Scholar
• Riou, J. F. et al. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl Acad. Sci. USA 99, 2672–2677 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, M. M. et al. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc. Natl Acad. Sci. USA 98, 7982–7987 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Minev, B. et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97, 4796–4801 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Nair, S. K. et al. Induction of cytotoxic T lymphocyte responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med. 6, 1011–1017 (2000).
  Article CAS PubMed Google Scholar
• Vonderheide, R. H. et al. Vaccination of cancer patients against telomerase induces functional anti-tumor CD8+ T lymphocytes. Clin. Cancer Res. 10, 828–839 (2004). First intradermal immunotherapy trial directed against telomerase in patients with breast cancer resistant to conventional cytotoxic therapy or progressive hormone-independent prostate cancer.
  Article CAS PubMed Google Scholar
• Vonderheide, R. H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21, 674–679 (2002).
  Article CAS PubMed Google Scholar
• Brunsvig, P. F. et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 21 Feb 2006 [epub ahead of print].
• Su, Z. et al. Telomerase mRNA-tranfected dendritic cells stimulate antigen-specific CD8+ and CD4+ cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798–3807 (2005). First immunotherapy trial directed against telomerase (hTERT) mRNA-transfected dendritic cells in patients with metastatic prostate cancer.
  Article CAS PubMed Google Scholar
• Chen, Z., Koeneman, K. S. & Corey, D. R. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res. 63, 5917–5925 (2003).
  CAS PubMed Google Scholar
• Gaudernack, G. et al. Clinical trials of a peptide vaccine targeting telomerase. ASCO Annu. Mtg A666 (2003).
• Corey, D. R. Telomerase: an unusual target for cytotoxic agents. Chem. Res. Toxicol. 13, 957–960 (2000).
  Article CAS PubMed Google Scholar
• Dikmen, Z. G. et al. In vivo inhibition of lung cancer by GRN163L — a novel human telomerase inhibitor. Cancer Res. 65, 7866–7873 (2005). First demonstration that the telomerase inhibitor GRN163L prevents lung metastasis in a xenograft animal model.
  Article CAS PubMed Google Scholar
• Gellert, G. C., Dikmen, Z. G., Wright, W. E., Gryaznov, S. & Shay, J. W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treatment (in the press).
• Djojosubroto, M. W. et al. Telomerase antagonist GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. (in press, Hepatology, 2006)
• Gryaznov, S. et al. Telomerase inhibitors – oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 20, 401–410 (2001).
  Google Scholar
• Herbert, B.-S. et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA 96, 14276–14281 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Herbert, B-S., Pongracz, K. Shay, J. W. & Gryaznov, S. M. Oligonucleotide N3′-P5′ phosphoramidates as efficient telomerase inhibitors Oncogene 21, 638–642 (2002).
  Article PubMed Google Scholar
• Asai, A. et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931–3939 (2003).
  CAS PubMed Google Scholar
• Gu, J. et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 60, 5359–5364 (2001).
  Google Scholar
• Gu, J., Andreff, M., Roth, J. A. & Fang, B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 9, 30–37 (2002).
  Article CAS PubMed Google Scholar
• Koga, S. et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 11, 1397–1406 (2000).
  Article CAS PubMed Google Scholar
• Koga, S. et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 21, 1937–1943 (2001).
  CAS PubMed Google Scholar
• Komata, T. et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796–5802 (2001).
  CAS PubMed Google Scholar
• Majumdar, A. S. et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 8, 568–578 (2001).
  Article CAS PubMed Google Scholar
• Abdul-Ghani, R. et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2, 539–544 (2000).
  Article CAS PubMed Google Scholar
• Plumb, J. A. et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20, 7797–7803 (2001).
  Article CAS PubMed Google Scholar
• Bilsland, A. E., Fletcher-Monaghan, A. & Keith, W. N. Properties of a telomerase-specific cre/lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 10, 1–10 (2006).
  Google Scholar
• Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
  Article CAS PubMed Google Scholar
• Goodell, M. A. et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nature Med. 3, 1337–1345 (1997).
  Article CAS PubMed Google Scholar
• Wang, J. C. Y. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 1, 494–501 (2005).
  Article CAS Google Scholar
• Bjerkvig, R., Tysnes, B. B., Aboody, K. S., Najbauer, J. & Terzis, A. J. A. The origin of the cancer stem cells: current controversies and new insights. Nature Rev. Genet. 5, 899–904 (2005).
  Article CAS Google Scholar
• Welm, B. E. et al. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev. Biol. 245, 42–56 (2002).
  Article CAS PubMed Google Scholar
• Clayton, H., Titley, I. & Vivanco, M. Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp. Cell Res. 297, 444–460 (2004).
  Article CAS PubMed Google Scholar
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ponit, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506–5511 (2005). First paper to demonstrate telomerase activity in cancer stem cells
  Article Google Scholar
• Campbell, L. J. et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 20, 671–679 (2006).
  Article CAS PubMed Google Scholar
• Wang, J. C. Y. et al. Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells. Proc. Natl Acad. Sci. USA 102, 14398–14403 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Shay, J. W., Pereira-Smith, O. M. & Wright, W. E. A role for both Rb and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196, 33–39 (1991).
  Article CAS PubMed Google Scholar
• Shay, J. W., Wright, W. E. & Werbin, H. Defining the molecular mechanisms of human cell immortalization. Biochim. Biophys. Acta 1072, 1–7 (1991).
  CAS PubMed Google Scholar
• Wright, W. E. & Shay, J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11, 98–103 (2001).
  Article CAS PubMed Google Scholar
• Zou, Y., Sfeir, A., Shay, J. W. & Wright, W. E. Does a sentinel or groups of short telomeres determine replicative senescence? Mol. Biol. Cell. 15, 3709–3718 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Goytisolo, F. A & Blasco, M. A. Many ways to telomere dysfunction: in vivo studies using mouse models. Oncogene 21, 584–591(2002).
  Article CAS PubMed Google Scholar
• Maser, R. S. & DePinho, R. A. Connecting chromosomes, crisis and cancer. Science 297, 565–569 (2002).
  Article CAS PubMed Google Scholar
• Feldser, D. M., Hackett, J. A. & Greider, C. W. Telomere dysfunction and the initiation of genome instability. Nature Rev. Cancer 3, 1–5 (2003).
  Article CAS Google Scholar
• Dokal, I. & Vulliamy T. in Telomeres 2nd Edn (Eds. deLange, T., Lundblad, V. Blackburn, E.) 139–161 (Cold Spring Harbor Laboratory, New York, 2005).
  Google Scholar
• Gomez, D. et al. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucl. Acids Res. 31, 371–379 (2004).
  Article Google Scholar
• Cristofari, G. & Lingner, J. in Telomeres 2nd Edn (Eds. deLange, T., Lundblad, V. Blackburn, E.) 21–47 (Cold Spring Harbor Laboratory, New York, 2005).
  Google Scholar
• Chen, J-L. & Greider, C. W. in Telomeres 2nd Edn (Eds. deLange, T., Lundblad, V. Blackburn, E.) 49–79 (Cold Spring Harbor Laboratory, New York, 2005).
  Google Scholar